World Health Organization Raises Alert Over Acute Scarcity of Obesity Jabs
Fewer than one in 10 people who could benefit from weight-loss injections such as Wegovy can access them, warns the WHO as it issues its inaugural guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer access to these injectable treatments.
According to estimates, over two billion could be obese by 2030 without intervention.
"The new guidance acknowledges that obesity is a lifelong illness that can be treated with comprehensive and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major obstacles to universal availability to the injections that can aid individuals in losing considerable body mass, says the body.
Weight-Loss Drug Scarcity
Despite the present most favorable outlook, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline calls on nations and manufacturers to expand availability, through approaches such as voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.
How Obesity Jabs Work
The injections mimick a biological compound to reduce digestion speed, curb appetite and increase satiety so people eat less.
Patients typically begin shedding pounds after several weeks of beginning the regular doses.
Evidence suggests patients may regain a significant portion a year later of stopping the medication, when their normal food cravings resume.
Being overweight or obese elevates your risk for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the health agency.
